Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Institute of Mental Health, Mannheim
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Major depressive episode, Severity: CDSS at least 8 points or HAMD at least 15 points, indication for the treatment with duloxetine

• Lifetime diagnosis of a psychotic disorder (PANSS positive scale below 15 points)

• Age between 18 and 65,

• Informed consent

Exclusion Criteria:

• No informed consent,

• Contraindications with respect to duloxetine,

• Gravidity or missing anticonceptive safety

• Substance dependance (excluded nicotin)